Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TLR4/MD-2 is a receptor for extracellular nucleophosmin 1.
Nakatomi K, Ueno H, Ishikawa Y, Salim RC, Mori Y, Kanemoto I, Tancharoen S, Kikuchi K, Miura N, Omori T, Okuda-Ashitaka E, Matsumura K, Imaizumi H, Motomiya Y, Maruyama I, Kawahara KI. Nakatomi K, et al. Biomed Rep. 2021 Feb;14(2):21. doi: 10.3892/br.2020.1397. Epub 2020 Dec 2. Biomed Rep. 2021. PMID: 33335727 Free PMC article.
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Tomono H, Taniguchi H, Fukuda M, Ikeda T, Nagashima S, Akagi K, Ono S, Umeyama Y, Shimada M, Gyotoku H, Takemoto S, Hisamatsu Y, Morinaga R, Tagawa R, Ogata R, Dotsu Y, Senju H, Soda H, Nakatomi K, Hayashi F, Sugasaki N, Kinoshita A, Mukae H. Tomono H, et al. Among authors: nakatomi k. Thorac Cancer. 2023 Oct;14(28):2890-2894. doi: 10.1111/1759-7714.15097. Epub 2023 Sep 7. Thorac Cancer. 2023. PMID: 37675546 Free PMC article.
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Ogusu S, Harutani Y, Tozuka T, Saito R, Koyama J, Sakamoto H, Sonoda T, Tsuchiya-Kawano Y, Oba T, Kudo K, Gyotoku H, Nakatomi K, Ariyasu R. Ogusu S, et al. Among authors: nakatomi k. Cancer Immunol Immunother. 2023 Nov;72(11):3765-3772. doi: 10.1007/s00262-023-03528-x. Epub 2023 Aug 28. Cancer Immunol Immunother. 2023. PMID: 37638979 Free PMC article.
Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Iwasaku M, Uchino J, Chibana K, Tanzawa S, Yamada T, Tobino K, Uchida Y, Kijima T, Nakatomi K, Izumi M, Tamiya N, Kimura H, Fujita M, Honda R, Takumi C, Yamada T, Kaneko Y, Kiyomi F, Takayama K. Iwasaku M, et al. Among authors: nakatomi k. Cancer Med. 2023 Jul;12(14):15117-15127. doi: 10.1002/cam4.6184. Epub 2023 Jun 3. Cancer Med. 2023. PMID: 37269194 Free PMC article. Clinical Trial.
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers.
Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M. Kurose K, et al. Among authors: nakatomi k. Adv Clin Chem. 2023;112:155-204. doi: 10.1016/bs.acc.2022.09.004. Epub 2022 Nov 17. Adv Clin Chem. 2023. PMID: 36642483 Review.
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study.
Akagi K, Taniguchi H, Fukuda M, Yamazaki T, Ono S, Tomono H, Suyama T, Shimada M, Gyotoku H, Takemoto S, Yamaguchi H, Dotsu Y, Senju H, Soda H, Mizowaki T, Monzen Y, Ikeda T, Nagashima S, Tasaki Y, Nakamura D, Komiya K, Nakatomi K, Sasaki E, Hirakawa K, Mukae H. Akagi K, et al. Among authors: nakatomi k. Thorac Cancer. 2022 Aug;13(16):2404-2409. doi: 10.1111/1759-7714.14555. Epub 2022 Jul 8. Thorac Cancer. 2022. PMID: 35808894 Free PMC article.
66 results